drugset / Trial / NCT00191659

Study of Broader Efficacy of Atomoxetine in the Treatment of ADHD in Children/Adolescents

NCT00191659

Phase 3 Completed 200 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

To test the hypothesis that children/adolescents with ADHD, who are treated with atomoxetine hydrochloride in comparison to standard current therapies have greater improvements in their quality of life.

Timeline

Start
2004-06
Primary completion
Completion
2006-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified